Table 2.
Summary of the Pooled Prevalence Estimates of Gastrointestinal/Liver Manifestations
| GI and liver manifestations | All studies |
Studies from China |
Studies from countries other than China |
|||
|---|---|---|---|---|---|---|
| % (95% CI) | Patients/ studies, n | % (95% CI) | Patients/ studies, n | % (95% CI) | Patients/ studies, n | |
| Diarrhea in all patientsa | 7.7 (7.2 to 8.2) | 43/10,676 | 5.8 (5.3 to 6.4) | 32/8612 | 18.3 (16.6 to 20.1) | 11/2064 |
| Nausea/vomiting in all patientsa | 7.8 (7.1 to 8.5) | 26/5955 | 5.2 (4.4 to 5.9) | 19/4054 | 14.9 (13.3 to –16.6) | 7/1901 |
| Abdominal pain in all patientsa | 3.6 (3.0 to 4.3) | 15/4031 | 2.7 (2.0 to 3.4) | 10/2447 | 5.3 (4.2 to 6.6) | 5/1584 |
| Patients with elevated AST | 15.0 (13.6 to 16.5) | 16/2514 | 14.9 (13.5 to 16.4) | 14/2398 | 20.0 (12.8 to 28.1) | 2/116 |
| Patients with elevated ALT | 15.0 (13.6 to 16.4) | 17/2711 | 14.9 (13.5 to 16.3) | 15/2595 | 19.0 (12.0 to 27.1) | 2/116 |
| Patients with elevated total bilirubin | 16.7 (15.0 to 18.5) | 10/1841 | 16.7 (15.0 to 18.5) | 10/1841 | — | — |
a
Regardless of hospitalization and timing of symptoms.